Edition:
United States

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

20.05USD
15 Dec 2017
Change (% chg)

$-0.84 (-4.02%)
Prev Close
$20.89
Open
$21.00
Day's High
$21.15
Day's Low
$19.73
Volume
1,535,188
Avg. Vol
204,700
52-wk High
$53.89
52-wk Low
$19.73

Latest Key Developments (Source: Significant Developments)

Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Five Prime Therapeutics Inc :Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors.Bristol-Myers Squibb - ‍Preliminary results show safety profile of Cabiralizumab plus Opdivo was generally consistent with that of Opdivo monotherapy​.Bristol-Myers Squibb - ‍Early efficacy signal observed in heavily pretreated patients with advanced pancreatic cancer with microsatellite stable disease​.Bristol-Myers Squibb Co - ‍Bristol-Myers Squibb is launching a new study of Cabiralizumab plus Opdivo​.Bristol-Myers Squibb Co - ‍Data show for first time that combining an anti-csf-1 receptor antibody with Opdivo may help restore t cell function​.  Full Article

Five Prime posts Q3 loss of $1.54 per share
Monday, 6 Nov 2017 04:05pm EST 

Nov 6 (Reuters) - Five Prime Therapeutics Inc :Five prime announces third quarter 2017 results and provides business update.Q3 loss per share $1.54.Q3 earnings per share view $-1.24 -- Thomson Reuters I/B/E/S.Five prime therapeutics inc - ‍collaboration revenue for q3 of 2017 increased by $1.6 million to $8.3 million​.  Full Article

Five Prime Therapeutics appoints Aron Knickerbocker as CEO
Monday, 23 Oct 2017 04:05pm EDT 

Oct 23 (Reuters) - Five Prime Therapeutics Inc :Five Prime Therapeutics announces appointment of Aron Knickerbocker as CEO effective January 1, 2018.Five Prime Therapeutics Inc - ‍ selected Aron Knickerbocker to succeed Lewis Williams, as president and CEO​.Five Prime Therapeutics Inc - ‍ Knickerbocker will maintain chief operating officer position until end of 2017​.  Full Article

Five Prime Therapeutics delivered to Inhibrx written notice of termination of agreement
Monday, 28 Aug 2017 04:09pm EDT 

Aug 28 (Reuters) - Five Prime Therapeutics Inc :‍Pursuant to terms of agreement, termination of agreement will become effective on december 27, 2017 (not 'december 27, 201')​.On august 28, 2017, Fiveprime delivered to Inhibrx written notice of termination of agreement for convenience​.  Full Article

Five Prime Therapeutics Q2 loss per share $1.58
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Five Prime Therapeutics Inc :Five Prime announces second quarter 2017 results and provides business update.Q2 loss per share $1.58.Q2 earnings per share view $-1.21 -- Thomson Reuters I/B/E/S.Five Prime Therapeutics - ‍cash, cash equivalents and marketable securities totaled $350.7 million on June 30, 2017, compared to $421.7 million on Dec 31, 2016​.Five Prime Therapeutics Inc - ‍collaboration revenue for Q2 of 2017 decreased by $1.4 million to $7.8 million from $9.2 million in Q2 of 2016​.Five Prime Therapeutics Inc - expects full-year 2017 net cash used in operating activities to be less than $120 million​.Five Prime Therapeutics Inc - ‍estimates ending 2017 with slightly less than $300 million in cash, cash equivalents and marketable securities​.  Full Article

Five Prime Therapeutics plans to initiate a global pivotal trial of FPA144 in 2018
Monday, 17 Jul 2017 04:10pm EDT 

July 17 (Reuters) - Five Prime Therapeutics Inc :Five prime Therapeutics initiates patient dosing in phase 1 clinical safety trial evaluating FPA144 in gastric cancer in Japan in preparation for future global late-stage development.Plans to initiate a global pivotal trial of FPA144 in 2018.  Full Article

Five Prime Therapeutics says Lewis Williams to be chairman of board in 2018
Wednesday, 21 Jun 2017 04:05pm EDT 

June 21 (Reuters) - Five Prime Therapeutics Inc ::Five Prime Therapeutics announces Lewis T. "Rusty" Williams plans to transition from CEO to executive chairman of the board in 2018.Says Dr. Williams will remain in his current role until new CEO has been appointed.Five Prime Therapeutics Inc - board will conduct a comprehensive search for a candidate to fill ceo position.Five Prime - Williams has discussed with board his desire to eventually return to executive chairman role while maintaining active role in Five Prime.  Full Article

Five Prime Therapeutics Q1 loss per share $1.21
Thursday, 4 May 2017 04:05pm EDT 

May 4 (Reuters) - Five Prime Therapeutics Inc :Five Prime announces first quarter 2017 results and provides business update.Q1 loss per share $1.21.Q1 earnings per share view $-1.03 -- Thomson Reuters I/B/E/S.Five Prime Therapeutics - company estimates ending 2017 with approximately $300 million in cash, cash equivalents and marketable securities.  Full Article

Five Prime Therapeutics announces completion of enrollment for the phase 2 of the ongoing trial of Cabiralizumab
Monday, 10 Apr 2017 04:05pm EDT 

Five Prime Therapeutics Inc : Five Prime Therapeutics announces completion of enrollment for the phase 2 part of the ongoing trial of cabiralizumab for the treatment of pigmented villonodular synovitis (PVNS) . Five Prime Therapeutics Inc - Five Prime plans to seek regulatory feedback on design of a pivotal trial .Five Prime Therapeutics - plans to present initial data from phase 2 part of trial at 2017 American Society Of Clinical Oncology (ASCO) annual meeting.  Full Article

Five Prime announces fourth quarter and full year 2016 financial results
Thursday, 23 Feb 2017 04:05pm EST 

Five Prime Therapeutics Inc : Five Prime announces fourth quarter and full year 2016 financial results . Q4 loss per share $0.73 .Q4 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors

* Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors